We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Mawi DNA

Mawi DNA Technologies develops unique biosample collection technologies enabling universal sample collection from any... read more Featured Products: More products

Download Mobile App





Swab with Unique Head Design Enables Accurate, More Reliable COVID-19 Test Results

By LabMedica International staff writers
Posted on 11 May 2022
Print article
Image: NextSWAB enables accurate, more reliable COVID-19 test results (Photo courtesy of Mawi DNA)
Image: NextSWAB enables accurate, more reliable COVID-19 test results (Photo courtesy of Mawi DNA)

Current sample collection methods for COVID-19 testing commonly face problems of low recovery, high bacterial content, low quality DNA, and excessive resampling costs. Now, a newly-launched 100% medical-grade plastic swab is designed for high efficiency collection without the possibility of contamination from glue or fibers used in flock and cotton swabs that may inhibit PCR based assays.

In response to the COVID-19 swab shortage, Mawi DNA Technologies (Hayward, CA, USA) has launched the NextSWAB that is currently optimized for nasal sample collection with validation for other sample types ongoing. The NextSWAB is compatible with many sample transport tubes making it ideal for multiple swab sample pooling in a single tube. However, to achieve optimal results, it is most effective when used in conjunction with Mawi’s iSWAB-Microbiome-EL sample collection technology which allows users to skip the RNA extraction step in COVID-19 molecular tests. A second nasal sample can be added to the same tube creating a more concentrated sample to improve overall reliability of the test. The NextSWAB comes ready for use and does not require any preparation for specimen collection.

“The NextSWAB sterile sampling applicator is six inches in length with a unique head design positioned at the distal end,” said Dr. Bassam El-Fahmawi, CEO of Mawi. “The swab head has two channels separated by a septum that retains the collected nasal material which can then be released into the transport media with a gentle shake. The flexible head fits into crevices with ease and effectiveness. It enables anterior nasal sample collection with minimal user discomfort sufficient for a meaningful result.”

“Our NextSWAB fully releases its contents into the sample transport media removing the need for the swab to be transported with the sample,” added Dr. El-Fahmawi. “A fully concentrated liquid sample can then be quickly processed with robotic liquid handling systems or any laboratory workflow. During initial R&D testing, the unique and patent pending head design has shown higher collection efficiency for nasal (mid-turbinate and anterior nares) samples than flocked swabs.”

Related Links:
Mawi DNA Technologies 

Gold Supplier
SARS-CoV-2 Antigen Rapid Test
RapiSafe SARS-CoV-2 Antigen Rapid Test (Professional use)
New
Automated Hematology Workstation
XN-3000
New
Zika Virus IgM µ-Capture ELISA
https://www.ibl-international.com/en/zika-virus-igm-capture-elisa
New
Dual-Channel Optical Coagulation Analyzer
Sensa2

Print article
IIR Middle East

Channels

Technology

view channel
Image: OneDraw Blood Collection Device significantly reduces obstacles for drawing blood (Photo courtesy of Drawbridge Health)

Near Pain-Free Blood Collection Technology Enables High-Quality Testing

Blood tests help doctors diagnose diseases and conditions such as cancer, diabetes, anemia, and coronary heart disease, as well as evaluate organ functionality. They can also be used to identify disease... Read more

Industry

view channel
Image: The global infectious disease IVD market is expected to hit USD 57 billion by 2030 (Photo courtesy of Pexels)

Global Infectious Disease IVD Market Dominated by Molecular Diagnostics Technology

The global infectious disease in vitro diagnostics (IVD) market stood at USD 113.7 billion in 2021 and is expected to grow at a CAGR of -7.41% from 2022 to 2030 to hit around USD 56.89 billion by 2030,... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.